Pappas Capital Announces the Passing of…

Syndax, a privately-held biopharmaceutical company focused on developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens, announced today the closing of a $40 million Series A financing. Syndax was co-founded by Eckard Weber, M.D., Domain Associates, and Ronald Evans, Ph.D, Salk Institute for Biological Studies and Howard Hughes Medical Institute. The financing was co- led by Domain Associates and MPM Capital. Co-investors include Avalon Ventures, Forward Ventures, and Pappas Ventures. The proceeds of the Series A will be used to fund development of a clinical pipeline.